Actinium Pharmaceuticals (ATNM) Total Current Liabilities (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Total Current Liabilities of $7.3 million for Q1 2026, up 3.36% year-over-year from $7.1 million in Q1 2025, and down 7.78% quarter-over-quarter from $8.0 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Total Current Liabilities (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Total Current Liabilities for 17 consecutive years, with $7.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 3.36% year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $7.3 million (up 3.36% YoY), while the FY2025 annual figure was $8.0 million, down 2.2% from the prior year.
- Total Current Liabilities slipped to $7.3 million in Q1 2026 per ATNM's latest filing, from $8.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $10.6 million in Q4 2022 and bottomed at $5.7 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $8.0 million across 5 years, with a median of $8.1 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 99.28% — and 2023, when it dropped 20.08%.
- Actinium Pharmaceuticals' Total Current Liabilities stood at $10.6 million in 2022, then dropped by 20.08% to $8.5 million in 2023, then slipped by 4.07% to $8.1 million in 2024, then slipped by 2.2% to $8.0 million in 2025, then decreased by 7.78% to $7.3 million in 2026.
- Business Quant data shows ATNM's Total Current Liabilities at $7.3 million in Q1 2026, $8.0 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 630.93 Mn |
| 10 | Actinium Pharmaceuticals | 34.85 Mn | 34.85 Mn | - | 9.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.26 Mn |
| Mar 31, 2026 | 7.35 Mn |
| Dec 31, 2025 | 7.97 Mn |
| Sep 30, 2025 | 6.83 Mn |
| Jun 30, 2025 | 8.31 Mn |
| Mar 31, 2025 | 7.11 Mn |
| Dec 31, 2024 | 8.15 Mn |
| Sep 30, 2024 | 7.76 Mn |
| Jun 30, 2024 | 9.73 Mn |
| Mar 31, 2024 | 8.06 Mn |
| Dec 31, 2023 | 8.49 Mn |
| Sep 30, 2023 | 8.67 Mn |
| Jun 30, 2023 | 9.15 Mn |
| Mar 31, 2023 | 7.86 Mn |
| Dec 31, 2022 | 10.63 Mn |
| Sep 30, 2022 | 8.35 Mn |
| Jun 30, 2022 | 6.28 Mn |
| Mar 31, 2022 | 5.72 Mn |
| Dec 31, 2021 | 6.84 Mn |
| Sep 30, 2021 | 4.19 Mn |